<DOC>
	<DOCNO>NCT01581138</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety two oral regimen subject chronic hepatitis C receive treatment yet .</brief_summary>
	<brief_title>VX-222 + Telaprevir + Ribavirin 12 16 Weeks Treatment-Naive Subjects With Genotype 1a Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Subjects must genotype 1 chronic hepatitis C ( CHC ) laboratory evidence HCV infection least 6 month Screening Visit Subjects treatment na√Øve Subjects must documentation presence absence cirrhosis History clinical evidence significant unstable cardiac disease Evidence hepatic decompensation Diagnosed suspected hepatocellular carcinoma Any cause significant liver disease addition hepatitis C , may include limited malignancy hepatic involvement , hepatitis B , drugor alcoholrelated cirrhosis , autoimmune hepatitis , hemochromatosis , Wilson 's disease , nonalcoholic steatohepatitis , primary biliary cirrhosis History organ transplant , exception corneal transplant skin graft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>